Biovie Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:3em;'>BIV</div>
BIVI -- USA Stock  

USD 26.06  1.57  6.41%

70% of stocks are less volatile than Biovie, and 46% of all traded equity instruments are projected to make higher returns than the company over the 60 days investment horizon. As many old-fashioned traders are trying to avoid healthcare space, it makes sense to concentrate on Biovie Inc a little further and try to understand its current volatility patterns. We will cover the possibilities of Biovie's current volatility to continue through March.
Published over a week ago
View all stories for Biovie | View All Stories
Biovie (NASDAQ:BIVI) high volatility trend continues
This firm currently holds 62.5 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest Biovie is not taking enough advantage from borrowing. The company has a current ratio of 36.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Biovie holds a performance score of 25 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0398, which signifies not very significant fluctuations relative to the market. Let's try to break down what Biovie's beta means in this case. As returns on the market increase, Biovie returns are expected to increase less than the market. However, during the bear market, the loss on holding Biovie will be expected to be smaller as well. Although it is essential to pay attention to Biovie Inc historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Biovie Inc expected return of 3.05 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Biovie semi variance, and the relationship between the treynor ratio and daily balance of power to analyze future returns on Biovie.
Volatility is a rate at which the price of Biovie or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Biovie may increase or decrease. In other words, similar to Biovie's beta indicator, it measures the risk of Biovie and helps estimate the fluctuations that may happen in a short period of time. So if prices of Biovie fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.

How important is Biovie's Liquidity

Biovie financial leverage refers to using borrowed capital as a funding source to finance Biovie Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biovie financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biovie's total debt and its cash.

How Biovie utilizes its cash?

To perform a cash flow analysis of Biovie, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biovie is receiving and how much cash it distributes out in a given period. The Biovie cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Biovie Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (1.47 Million)

Biovie Volatility Drivers

Biovie unsystematic risk is unique to Biovie Inc and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Biovie you can also buy Equillium. You can also mitigate this risk by investing in the biotechnology sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Biovie important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Biovie income statement and balance sheet. Here are more details about Biovie volatility.
Click cells to compare fundamentals   

Purchase by Gorlin Steve of 2430 shares of Biovie

Legal trades by Biovie insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biovie insider trading alert for perchase of class a common stock par value $0.0001 by Gorlin Steve, the corporate stakeholder, on 15th of December 2020. This event was filed by Biovie Inc with SEC on 2020-12-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Biovie

Net Loss for the year was (68.84 M).

Over 3 percent rise for Biovie. What does it mean for stockholders?

Biovie current risk adjusted performance boosts over 0.24. Biovie Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biovie Inc independently to ensure intended market timing strategies are aligned with expectations about Biovie volatility.

Our Conclusion on Biovie

While other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Biovie may offer a potential longer-term growth to stockholders. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take over new shares of Biovie nor sell your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biovie.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Biovie Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to